JP2022502079A5 - - Google Patents
Info
- Publication number
- JP2022502079A5 JP2022502079A5 JP2021540778A JP2021540778A JP2022502079A5 JP 2022502079 A5 JP2022502079 A5 JP 2022502079A5 JP 2021540778 A JP2021540778 A JP 2021540778A JP 2021540778 A JP2021540778 A JP 2021540778A JP 2022502079 A5 JP2022502079 A5 JP 2022502079A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- fragment according
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733435P | 2018-09-19 | 2018-09-19 | |
| US201862733443P | 2018-09-19 | 2018-09-19 | |
| US201862733444P | 2018-09-19 | 2018-09-19 | |
| US62/733,443 | 2018-09-19 | ||
| US62/733,435 | 2018-09-19 | ||
| US62/733,444 | 2018-09-19 | ||
| PCT/US2019/051967 WO2020061337A1 (en) | 2018-09-19 | 2019-09-19 | Cancer associated antibody compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502079A JP2022502079A (ja) | 2022-01-11 |
| JP2022502079A5 true JP2022502079A5 (enExample) | 2022-11-01 |
Family
ID=69888817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540778A Pending JP2022502079A (ja) | 2018-09-19 | 2019-09-19 | がん関連抗体組成物および使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12285484B2 (enExample) |
| EP (1) | EP3853377A4 (enExample) |
| JP (1) | JP2022502079A (enExample) |
| AU (1) | AU2019342131A1 (enExample) |
| CA (1) | CA3113223A1 (enExample) |
| WO (1) | WO2020061337A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12252525B2 (en) | 2020-07-31 | 2025-03-18 | Nantbio, Inc. | Chimeric T cell receptors, nucleic acids, and methods of making and using the same |
| AU2021395241A1 (en) * | 2020-12-07 | 2023-06-22 | Target Discovery Merger Sub II, LLC | Systems and methods for producing disease-associated protein compositions |
| CN114106187B (zh) * | 2022-01-05 | 2023-01-24 | 中国海洋大学 | 一种靶向ogt的特异性鲨鱼单域抗体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124317D0 (en) * | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| PT1848744E (pt) * | 2005-01-27 | 2012-04-24 | Novimmune Sa | Anticorpos anti-interferão gama e os seus processos de utilização |
| US8759490B2 (en) * | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| WO2008063346A2 (en) | 2006-10-26 | 2008-05-29 | The Research Foundation Of State University Of New York | IL-14α RNA INHIBITORS AND ANTIBODIES TO IL-14α FOR TREATMENT OF AUTOIMMUNE DISEASES AND LYMPHOMAS |
| US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| WO2009085383A1 (en) * | 2007-12-19 | 2009-07-09 | Dcb-Usa Llc | Anti-human cytomegalovirus antibodies |
| CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
| PT3277821T (pt) * | 2015-03-31 | 2019-10-31 | Novimmune Sa | Método para otimizar a montagem e produção de complexos proteicos hetero-multiméricos |
| EP4019552A1 (en) * | 2015-06-10 | 2022-06-29 | National Research Council of Canada | Carbonic anhydrase ix-specific antibodies and uses thereof |
| EP3332637A1 (en) * | 2016-12-09 | 2018-06-13 | Universitätsklinikum Hamburg-Eppendorf | Vhh-containing heavy chain antibody and production thereof |
-
2019
- 2019-09-19 AU AU2019342131A patent/AU2019342131A1/en not_active Abandoned
- 2019-09-19 WO PCT/US2019/051967 patent/WO2020061337A1/en not_active Ceased
- 2019-09-19 CA CA3113223A patent/CA3113223A1/en active Pending
- 2019-09-19 EP EP19861397.8A patent/EP3853377A4/en active Pending
- 2019-09-19 JP JP2021540778A patent/JP2022502079A/ja active Pending
- 2019-09-19 US US17/277,214 patent/US12285484B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| JP2021516974A5 (enExample) | ||
| JP6866294B2 (ja) | 抗ｐｄ−ｌ１抗体 | |
| JP2021533726A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2021515568A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2021516976A5 (enExample) | ||
| JP2021516975A5 (enExample) | ||
| JP2021515566A5 (enExample) | ||
| CN116769035A (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| CN107530429A (zh) | 特异性针对糖基化的pd‑l1的抗体及其使用方法 | |
| JP2022533538A5 (enExample) | ||
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2017521054A5 (enExample) | ||
| US20210040213A1 (en) | Immunomonotherapy for urothelial carcinoma | |
| JP2025507938A (ja) | 抗ｐｄ－ｌ２抗体 | |
| JP2022502079A5 (enExample) | ||
| JP2025524306A (ja) | Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体 | |
| EP4534562A1 (en) | Bispecific antibody and application thereof | |
| WO2023222135A9 (en) | A method of treating solid tumor | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| EP4582450A1 (en) | Anti-pvrig antibody and application thereof | |
| HK40120258A (zh) | 治疗实体瘤的方法 |